Stereochemistry of an agonist determines coupling preference of β 2-adrenoceptor to different g proteins in cardiomyocytes

Molecular Pharmacology

Volumn 75, Issue 1, 2009, Pages 158-165

  Woo, Anthony Yiu Ho ^a,d   Wang, Tian Bing ^a,c   Zeng, Xiaokun ^a   Zhu, Weizhong ^a   Abernethy, Darrell R ^b   Wainer, Irving W ^b   Xiao, Rui Ping ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; FENOTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; METHOXYFENOTEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUSSIS TOXIN; PROTEIN GI2; PROTEIN GI3; RECEPTOR SUBTYPE; SERINE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL CELL; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; ISOMER; MALE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STEREOISOMERISM; ADENOVIRUS; AFFINITY LABELING; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENE TRANSFER; GENETICS; HEART CONTRACTION; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADENOVIRIDAE; ADRENERGIC BETA-AGONISTS; AFFINITY LABELS; ANIMALS; CELLS, CULTURED; FENOTEROL; GENE TRANSFER TECHNIQUES; GTP-BINDING PROTEINS; HUMANS; MALE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-2; STEREOISOMERISM;

EID: 58849137169     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.051078     Document Type: Article

References (40)

1. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, and Talan MI (2004) Beneficial effects of chronic pharmacological manipulation of β-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110:1083-1090.
2. 1 AR blocker in dilated cardiomyopathy post-myocardial infarction. J Pharmacol Exp Ther 325:491-499.
3. 1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10:289-296.
4. i/o activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. Br J Pharmacol 132:950-958.
5. Beigi F, Bertucci C, Zhu W, Chakir K, Wainer IW, Xiao RP, and Abernethy DR (2006) Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. Chirality 18:822-827.
6. Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O, Bienert M, and Berger H (2007) Achieving signalling selectivity of ligands for the corticotro-pin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol 151:851-859.
7. iα, in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 26:133-149.
8. 1-receptor down-regulation in heart failure. Circ Res 59:297-309.
9. 1 receptor messenger RNA abundance in the failing human heart. JClin Invest 92:2737-2745.
10. Cordeaux Y, Ijzerman AP, and Hill SJ (2004) Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol 143:705-714.
11. 2 dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 276:28667-28675.
12. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91.
13. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, and Van Dop C (1988) Increase ofthe 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. JClin Invest 82:189-197.
14. i switching. Mol Pharmacol 62:1094-1102.
15. αo G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
16. 2 adren-ergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270:28268-28275.
17. 2-adrenergic receptor. J Biol Chem 276: 24433-24436.
18. 2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 282:13895-13905.
19. 2+ channels in canine heart failure. Circ Res 97:566-573.
20. 2- adrenoceptor sites Ser262 and Ser355,356. Br JPharmacol 147:249-259.
21. 2 adrenergic receptor. J Med Chem 50:2903-2915.
22. Kenakin T (2004) Principles: Receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
23. Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415.
24. Kobilka BK and Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406.
25. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
26. 2+ -exchanger. J Mol Cell Cardiol 36:43-48.
27. 2-Adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein Rap1 and the serine/threonine kinase B-Raf. J Biol Chem 275:25342-25350.
28. 2 adrenergic receptor. J Biol Chem 281:1261-1273.
29. Sun Y, Huang J, Xiang Y, Bastepe M, Jüppner H, Kobilka BK, Zhang JJ, and Huang XY (2007) Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 26:53-64.
30. 2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
31. 2- adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol 65:196-206.
32. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
33. Violin JD and Lefkowitz RJ (2007) β-Arrestin-biased ligands at seven-transmem-brane receptors. Trends Pharmacol Sci 28:416-422.
34. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84:43-52.
35. i signaling to heart failure: associated defect of adrenergic contractile support. J Mol Cell Cardiol 36:7-11.
36. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47:322-329.
37. 1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108:1633-1639.
38. Zheng M, Zhu W, Han Q, and Xiao RP (2005) Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 108: 257-268.
39. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 98:1607-1612.
40. i signaling in the heart: the good, the bad, and the ugly. Circ Res 97:507-509.